EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer

Annekatrin Schott, Theresa Simon, Simon Müller, Alexander Rausch, Bianca Busch, Markus Glaß, Danny Misiak, Mohammad Dipto, Hend Elrewany, Lara Meret Peters, Sunita Tripathee, Ehab Ghazy und 9 weitere

NAR Cancer · 15.01.2025 · 7 (1)

DOI: 10.1093/narcan/zcaf006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 24.02.2025. Verfasst von Annekatrin Schott und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Medicine, Section for Molecular Cell Biology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, 06120 Halle, Ger…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, RNA-Binding Proteins, Adaptor Proteins, Signal Transducing, Transcription Factors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: DFG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Hippo/YAP1 signaling pathway regulates normal development by controlling contact inhibition of growth. In cancer, YAP1 activation is often dysregulated, leading to excessive tumor growth and metastasis. SRC kinase can cross talk to Hippo signaling by disrupting adherens junctions, repressing the Hippo cascade, or activating YAP1 to promote proliferation. Here, we demonstrate that the IGF2 messenger RNA-binding protein 1 (IGF2BP1) impedes the repression of YAP1 by Hippo signaling in carcinomas. IGF2BP1 stabilizes the YAP1 messenger RNA (mRNA) and enhances YAP1 protein synthesis through an m6A-dependent interaction with the 3′ untranslated region of the YAP1 mRNA, thereby increasing YAP1/TAZ-driven transcription to bypass contact inhibition of tumor cell growth. Inhibiting IGF2BP1–mRNA binding using BTYNB reduces YAP1 levels and transcriptional activity, leading to significant growth inhibition in carcinoma cells and ovarian cancer organoids. In contrast, SRC inhibition with Saracatinib fails to inhibit YAP1/TAZ-driven transcription and cell growth in general. This is particularly significant in de-differentiated, rather mesenchymal carcinoma-derived cells, which exhibit high IGF2BP1 and YAP1 expression, rendering them less reliant on SRC-directed growth stimulation. In such invasive carcinoma models, the combined inhibition of SRC, IGF2BP1, and YAP1/TAZ proved superior over monotherapies. These findings highlight the therapeutic potential of targeting IGF2BP1, a key regulator of oncogenic transcription networks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsRNA-Binding ProteinsAdaptor Proteins, Signal TransducingTranscription FactorsGene Expression Regulation, NeoplasticHumansYAP-Signaling ProteinsFemaleCell Line, TumorCell ProliferationSignal TransductionRNA, MessengerOncogenes

Substanzen

YAP-Signaling ProteinsYAP1 protein, humanRNA-Binding ProteinsAdaptor Proteins, Signal TransducingTranscription FactorsIGF2BP1 protein, humanRNA, Messenger

Autor:innen und Institutionen

  • Institute of Molecular Medicine, Section for Molecular Cell Biology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.
  • New York Genome Center, 10013 New York, NY, United States; Department of Biology, New York University, 10003 New York, NY, United States.
  • Department of Pharmaceutical Chemistry and Bioanalytics, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Straße 3, 01620 Halle (Saale), Germany.
  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, 21163 Irbid, Jordan.
  • Department of Gynecology, University Hospital, Martin Luther University Halle-Wittenberg, Ernst-Grube-Straße 40, 01620 Halle (Saale), Germany.

ORCID-Profile: Stefan Hüttelmaier, Nadine Bley

Förderung

  • DFG

Zitieren

APA

Schott, A., Simon, T., Müller, S., Rausch, A., Busch, B., Glaß, M., Misiak, D., Dipto, M., Elrewany, H., Peters, L. M., Tripathee, S., Ghazy, E., Müller, F., Rolnik, R. B., Lederer, M., Hmedat, A., Vetter, M., Wallwiener, M., Sippl, W., …, & Bley, N. (2025). The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer. NAR Cancer, 7(1). https://doi.org/10.1093/narcan/zcaf006

Vancouver

Schott A, Simon T, Müller S, Rausch A, Busch B, Glaß M, et al. The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer. NAR Cancer. 2025;7(1). doi:10.1093/narcan/zcaf006

BibTeX
@article{Schott2025,
  author = {Schott, Annekatrin and Simon, Theresa and Müller, Simon and Rausch, Alexander and Busch, Bianca and Glaß, Markus and Misiak, Danny and Dipto, Mohammad and Elrewany, Hend and Peters, Lara Meret and Tripathee, Sunita and Ghazy, Ehab and Müller, Florian and Rolnik, Robin Benedikt and Lederer, Marcell and Hmedat, Ali and Vetter, Martina and Wallwiener, Markus and Sippl, Wolfgang and Hüttelmaier, Stefan and Bley, Nadine},
  title = {The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer},
  journal = {NAR Cancer},
  year = {2025},
  volume = {7},
  number = {1},
  doi = {10.1093/narcan/zcaf006}
}
Kostenlos starten →